Pfizer launches SpringWorks | October 2, 2017 Issue - Vol. 95 Issue 39 | Chemical & Engineering News
Volume 95 Issue 39 | p. 15 | Concentrates
Issue Date: October 2, 2017

Pfizer launches SpringWorks

By Ryan Cross
Department: Business
Keywords: Start-ups, Pfizer, desmoid tumor

New York City-based start-up SpringWorks Therapeutics has sprouted from Pfizer with the goal of providing a home for drugs orphaned by other companies but ready for a Phase II or III clinical study. President Lara S. Sullivan left her position as a Pfizer vice president to found SpringWorks, which garnered $103 million in series A funds from Bain Capital Life Sciences, Pfizer, and others. Its first move is to drive four potential therapies abandoned by Pfizer into advanced clinical trials for desmoid tumors, neurofibromatosis, hereditary xerocytosis, and posttraumatic stress disorder.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment